SI
MYGN icon

Sensato Investors’s Myriad Genetics MYGN Stock Holding History

Sensato Investors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-553,505
Closed -$16.4M – 103
2018
Q1 		$16.4M Buy
553,505
+517,605
+1,442% +$17.5M 2.54% 21
2017
Q4 		$1.23M Buy
+35,900
New +$1.21M 0.15% 64

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sensato Investors's MYGN Position: Q2 2018 in Review

Sensato Investors sold out of Myriad Genetics (MYGN) in Q2 2018, closing a stake of 553,505 shares — an estimated $16.4M sold.

Sensato Investors first reported a position in MYGN in Q4 2017 and held it in 2 quarters. The position peaked at $16.4M in Q1 2018. 258 funds tracked by Wall St. Rank hold MYGN as of Q2 2018.

  • Sensato Investors reported no remaining Myriad Genetics position as of Q2 2018 after selling out during the quarter.
  • Sensato Investors sold 553,505 Myriad Genetics shares in Q2 2018, an estimated $16.4M.
  • Sensato Investors first reported a position in Myriad Genetics in Q4 2017 and held it in 2 quarters.
  • Sensato Investors's Myriad Genetics position peaked at $16.4M in Q1 2018.
  • 258 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2018.

Based on Sensato Investors's 13F filing for Q2 2018, filed 14 Aug 2018.